| pubmed-article:15201502 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15201502 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15201502 | lifeskim:mentions | umls-concept:C0024623 | lld:lifeskim |
| pubmed-article:15201502 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:15201502 | lifeskim:mentions | umls-concept:C1521750 | lld:lifeskim |
| pubmed-article:15201502 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
| pubmed-article:15201502 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:15201502 | lifeskim:mentions | umls-concept:C1143759 | lld:lifeskim |
| pubmed-article:15201502 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:15201502 | pubmed:dateCreated | 2004-6-17 | lld:pubmed |
| pubmed-article:15201502 | pubmed:abstractText | Heptaplatin is a recently developed platinum derivative. This agent has been reported to have a response rate of 17% as a single agent, and tolerable toxicity in the treatment of advanced gastric cancer. The aim of this study was to evaluate the efficacy and toxicity of a combination of 5-fluorouracil (5-FU) and heptaplatin in patients with advanced gastric cancer. Forty-seven chemotherapy-naive patients with advanced or recurred gastric cancer were recruited. 5-FU was administered over 120 hr by continuous intravenous infusion from day 1 to 5, at a daily dose of 1,000 mg/m2 and heptaplatin was administered over 1 hr by intravenous infusion on day 1 at 400 mg/m2, and this cycle was repeated every 4 weeks. The response rate was 21%, median progression-free survival was 1.9 months (95% CI, 1.6 to 2.2 months). Median overall survival was 6.2 months (95% CI, 4 to 8.4 months) and the 1-yr survival rate was 29% for all patients. The most frequent toxicity was proteinuria. Toxicities were generally mild and reversible. This study demonstrates that the combination of 5-FU/heptaplatin combination is less active but tolerated in patients with advance gastric cancer. | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15201502 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15201502 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201502 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15201502 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15201502 | pubmed:issn | 1011-8934 | lld:pubmed |
| pubmed-article:15201502 | pubmed:author | pubmed-author:ShinJung... | lld:pubmed |
| pubmed-article:15201502 | pubmed:author | pubmed-author:ChoHong RaeHR | lld:pubmed |
| pubmed-article:15201502 | pubmed:author | pubmed-author:MinYoung... | lld:pubmed |
| pubmed-article:15201502 | pubmed:author | pubmed-author:ParkJae HooJH | lld:pubmed |
| pubmed-article:15201502 | pubmed:author | pubmed-author:KimDo HaDH | lld:pubmed |
| pubmed-article:15201502 | pubmed:author | pubmed-author:KoByung... | lld:pubmed |
| pubmed-article:15201502 | pubmed:author | pubmed-author:BangSung-JoSJ | lld:pubmed |
| pubmed-article:15201502 | pubmed:author | pubmed-author:KimGyu YeolGY | lld:pubmed |
| pubmed-article:15201502 | pubmed:author | pubmed-author:ChoiDae HwaDH | lld:pubmed |
| pubmed-article:15201502 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15201502 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:15201502 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15201502 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15201502 | pubmed:pagination | 369-73 | lld:pubmed |
| pubmed-article:15201502 | pubmed:dateRevised | 2010-9-20 | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:meshHeading | pubmed-meshheading:15201502... | lld:pubmed |
| pubmed-article:15201502 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15201502 | pubmed:articleTitle | Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer. | lld:pubmed |
| pubmed-article:15201502 | pubmed:affiliation | Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. yjmin@uuh.ulsan.kr | lld:pubmed |
| pubmed-article:15201502 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15201502 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15201502 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15201502 | lld:pubmed |
